The Effect of NADPH Oxidase and Creatine Supplementation on Microvascular Blood Flow Regulation

Endothelial Dysfunction Clinical Trial

— NOXCROS  

Official title:

NADPH Oxidase Affects on Blood Flow After Administering a High Carbohydrate Meal Pre- and Post-creatine Monohydrate Supplementation.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06018480
• Other study ID #: STUDY00003857
• Status: Completed
• Phase: N/A
• Start date: August 29, 2023
• Est. completion date: January 30, 2024

Study information

• Verified date: May 2024
• Source: Florida State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research study seeks to determine the effects of an enzyme in the human body called NADPH oxidase (NOX) on blood flow. In addition, the study will investigate the benefits of creatine monohydrate, a common sports performance supplement, on blood food and vessel function. Participants will undergo two study arms, one in which they consume a high carbohydrate meal pre- and post-creatine monohydrate supplementation and one in which they will consume a high carbohydrate meal pre- and post-placebo supplementation. Blood flow and endothelial function will be assessed before and for 4 hours following the consumption of a high-carbohydrate meal pre and post-supplementation (creatine monohydrate and placebo).

Description:

A double-blind cross-over placebo-controlled study design will be used to determine the extent to which NOX and creatine monohydrate supplementation influences skeletal muscle microvascular blood flow and endothelial function following the administration of a high carbohydrate meal in sedentary individuals with overweight/obesity. Participants will be initially screened through a telephone screening over the phone or through an electronic copy (Qualtrics survey) and upon meeting the inclusion criteria, will be scheduled for a baseline visit. At the baseline visits participants will go through an informed consent, background and medical history questionnaire alongside a Dual-energy X-ray absorptiometry (DXA) scan and indirect calorimetry. Subsequently, participants will undergo two main testing days, one will occur before supplementation (creatine monohydrate or placebo) and the other following five days of supplementation (creatine monohydrate or placebo). At the main testing days participants will have their resting blood flow and endothelial function assessed before and for 4 hours following the consumption of a high carbohydrate meal. Following the two main testing days in the first study arm, participants will then undergo a 4-week wash-out in which they will resume their normal behavior and stop taking the supplement they were provided. After the washout period, participants will come back and repeat the baseline visit and the two main testing days. The only difference is that participants will receive the other treatment that was not received the first time (creatine monohydrate or placebo). Which treatment the participant receives first or second will be at random.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: January 30, 2024
• Est. primary completion date: January 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Body Mass Index: 25.0-34.9 kg/m2
• Sedentary; sedentary status will be defined as not performing purposeful exercise training more than 20 minutes per day three a week.
• Currently residing in Tallahassee, Florida, or the surrounding area
• Not taking any medication(s) that interfere with metabolism.
• Not taking any antioxidant supplementation, at least four weeks before the study.
• Not supplementing with creatine monohydrate, at least four weeks before the study.
• Not smoking, vaping, or chewing tobacco and willing to refrain from smoking, vaping, and chewing tobacco throughout the entire study.
• Are not pregnant or planning on becoming pregnant

Exclusion Criteria:

• Metabolic or cardiovascular abnormalities, gastrointestinal disorders, and any

condition that interferes with metabolism or oxygen delivery/transport including:

• Diagnosed cardiovascular diseases or previous myocardial infarction.
• Uncontrolled hypertension (resting: above 140 mmHg systolic or 90 mmHg diastolic)
• Diabetes (Type 1 or 2)
• Uncontrolled thyroid conditions
• Cigarette smoking: current cigarette smoker or those who quit within the previous 6 months.
• Participants consuming supplements or medication known to impact metabolism.
• Participants already consuming creatine monohydrate
• Allergies or intolerance to foods included in the standardized and high carbohydrate meal.
• Women that are pregnant or planning on becoming pregnant
• Weight gain or loss > 10% of body weight during the past 6 months
• Participants consume a vegan or vegetarian diet.
• Non-English-speaking individuals, infants, children, teenagers, cognitively impaired adults individuals, and adults who are unable to consent will be recruited for the study.

Related Conditions & MeSH terms

• Endothelial Dysfunction

Intervention

Other:
• Creatine Monohydrate
The supplementation is the intervention.
• Maltodextrin (Placebo)
Placebo to Creatine Monohydrate

Locations

Country	Name	City	State
United States	Florida State University	Tallahassee	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Florida State University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concentrations of reactive oxygen species (ROS)	Reactive oxygen species measured with microdialysis, reported as hydrogen peroxide (H2O2) concentrations.	Change from pre to post five days of creatine monohydrate supplementation at 0, 1, 2, 3, 4 hours post high carbohydrate meal
Primary	Rate of skeletal muscle blood flow	Skeletal muscle microvascular blood flow measured with microdialysis reported as ethanol outflow/inflow ratio which is inversely with blood flow.	Change from pre to post five days of creatine monohydrate supplementation at 0, 1, 2, 3, 4 hours post high carbohydrate meal
Primary	Flow mediated dilation percentage	Endothelial function as measured with brachial artery flow-mediated dilation, reported as a percentage.	Change from pre to post five days of creatine monohydrate supplementation at 0, 1, 2, 3, 4 hours post high carbohydrate meal